1. Home
  2. BYFC vs CRDF Comparison

BYFC vs CRDF Comparison

Compare BYFC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadway Financial Corporation

BYFC

Broadway Financial Corporation

HOLD

Current Price

$11.60

Market Cap

90.3M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.88

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYFC
CRDF
Founded
1946
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.3M
86.8M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
BYFC
CRDF
Price
$11.60
$0.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
8.9K
850.2K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
0.07
N/A
Revenue
$184,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$165.72
N/A
Revenue Growth
18.71
49.61
52 Week Low
$5.51
$0.76
52 Week High
$12.31
$3.31

Technical Indicators

Market Signals
Indicator
BYFC
CRDF
Relative Strength Index (RSI) 69.02 37.55
Support Level $9.29 $0.76
Resistance Level N/A $1.13
Average True Range (ATR) 0.28 0.07
MACD 0.11 0.01
Stochastic Oscillator 69.13 16.83

Price Performance

Historical Comparison
BYFC
CRDF

About BYFC Broadway Financial Corporation

Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: